Phlexglobal, the provider of Trial Master File (TMF) software and services, announced the acquisition of Cunesoft, a move that expands the company’s portfolio of technologies designed to provide solution-specific functionality to meet the business objectives of life sciences companies.
Based in Munich, Germany, Cunesoft provides intelligent software and services for regulatory data management to the life sciences industry. Cunesoft customers benefit from solutions for Regulatory Information Management (RIM), Identification of Medicinal Products (IDMP) and Electronic Common Technical Document (eCTD) for compliant document, data and submission management. All of those capabilities are enhanced with Cune-Distiller, which uses advanced machine learning algorithms for automation, document data mining and data extraction that can result in rapid deployment and value creation.
“We will be offering customers two levels of immediate benefit with this acquisition” said Phlexglobal CEO John McNeill. “First, we will be providing a suite of solutions that will unify the relevant processes and data elements between the Clinical Operations and Regulatory departments of life sciences companies, combining our years of thought leadership in eTMF with Cunesoft’s expertise in regulatory. Second, and just as important, we will be leveraging Cunesoft’s Distiller solution to package that expertise into digitalized offerings to not only augment our own suite of solutions but to operate with any existing set of solutions that might already be in place.”
“The combination of Phlexglobal and Cunesoft comes at a critical time in regulatory transformation where higher operational efficiency and innovation are required,” said noted regulatory industry expert Steve Gens of Gens and Associates. “Most Life Sciences organizations are heavily investing in digitization and global operations to connect various regulatory, clinical, and safety capabilities; the combination of Phlexglobal and Cunesoft aligns with this critical trend.”
Since its founding in 2013, Cunesoft has been focused on digitalizing processes and building automation capabilities that can be applied to existing life sciences solutions, helping companies achieve outcomes faster without compromising quality. It was this capability that first brought the two companies together in a partnership in 2018.
“We partnered with Cunesoft to advance the automation capabilities of PhlexEview, our eTMF solution, and were extremely pleased with the outcome,” said Phlexglobal Chief Technology Officer Barry Sacks. “Over the course of our partnership, we developed many innovative ideas around how clinical and regulatory data can be contextualized into useful information, bringing drugs to market more efficiently. Now that Cunesoft is part of Phlexglobal, we can expand the use of AI, machine learning, and data mining to bring these ideas to life.”
Unique in the clinical trial industry for its ability to support both the technological and service needs of TMF Management, Phlexglobal cited Cunesoft’s deep experience in Regulatory services as an important consideration in moving ahead with this combination.
“The entire Cunesoft team is very excited about this new chapter in our story,” said Rainer Schwarz, Cunesoft co-founder and Chief Executive Officer. “Phlexglobal has a long history of providing expert services and software technology to its customers, and this will allow us to build on the work we have already done to advance and automate many of the processes crucial to the management of data for life-saving drugs and medical devices.”
McNeill stated “Phlexglobal has always been viewed as the experts in our space and Cunesoft brings that same DNA to the combined entity. We are especially pleased that Rainer and the rest of the Cunesoft team will be joining Phlexglobal as it brings a very talented group of people into the organization with domain expertise in the regulatory space as well as application of technology for automation and data mining. This will allow us to deliver solutions-both software and expert services-to address specific use cases that are not being solved today and to deliver higher value in terms of speed, efficiency and quality.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.